Krystal Biotech, Inc. (KRYS) Stock Analysis
A live, multi-source view of Krystal Biotech, Inc. (KRYS): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Sector: Healthcare · Industry: Biotechnology · United States · 295 employees · krystalbio.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Krystal Biotech, Inc. (KRYS) had a market capitalization of $10.60B, a trailing P/E of 44.9 (forward 38.1) and a beta of 0.54; the shares traded in a 52-week range of $136.73 – $382.54 (146.7% over the year).
- Market cap
- $10.60B
- Enterprise value
- $9.77B
- Trailing P/E
- 44.9
- Forward P/E
- 38.1
- Price / book
- 7.80
- EPS (trailing)
- $7.98
- EPS (forward)
- $9.40
- Payout ratio
- 0.0%
- 52-week range
- $136.73 – $382.54
- 52-week change
- 146.7%
- Beta
- 0.54
- Average volume
- 410,619
- Shares outstanding
- 29.6M
- Short % of float
- 17.73%
- Profit margin
- 54.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Krystal Biotech, Inc. (KRYS) last closed at $345.55 (the last completed close before that scan).
Technicals at the scan: RSI 48 (neutral territory), price -1.1% versus its 20-day average, 20-day versus 50-day average spread +0.4%, MACD histogram -0.79.
Sentiment inputs: analyst consensus score 75/100.
Next scheduled company event: in 52 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of KRYS; corporate insiders filed 0 buys and 34 sells (3 distinct filers, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Krish S. Krishnan (0B/13S), Suma Krishnan (0B/13S), Dino A. Rossi (0B/8S). Who is trading what
RapidTradeView pick record
KRYS has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Krystal Biotech, Inc. (KRYS) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell KRYS.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.